Literature DB >> 15954196

Developmental pathology, dopamine, and stress: a model for the age of onset of schizophrenia symptoms.

Judy L Thompson1, Michael F Pogue-Geile, Anthony A Grace.   

Abstract

It is unknown why the onset of schizophrenia is typically during late adolescence or early adulthood. The fact that numerous brain maturational processes normally occur during this age period has led researchers to postulate how such processes may be related to the onset of symptoms. To help elucidate the question of age of onset, we selectively review schizophrenia-associated abnormalities of dopamine and related systems, including glutamate and hypothalamic-pituitary-adrenal systems; relevant models of pathophysiology; and the systems' developmental aspects. Based on current findings and conceptualizations, a model is then proposed in which, during adolescence, interactive pathological and normal adolescence-associated processes trigger a positive feedback system that results in a rapid increase in pathology that is proposed to underlie the development of active psychotic symptoms during late adolescence or early adulthood.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15954196     DOI: 10.1093/oxfordjournals.schbul.a007139

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  54 in total

Review 1.  Disruption of cortical-limbic interaction as a substrate for comorbidity.

Authors:  A A Grace
Journal:  Neurotox Res       Date:  2006-10       Impact factor: 3.911

Review 2.  Fibroblast growth factors in schizophrenia.

Authors:  Afke F Terwisscha van Scheltinga; Steven C Bakker; René S Kahn
Journal:  Schizophr Bull       Date:  2009-05-08       Impact factor: 9.306

Review 3.  Perinatal Risks and Childhood Premorbid Indicators of Later Psychosis: Next Steps for Early Psychosocial Interventions.

Authors:  Cindy H Liu; Matcheri S Keshavan; Ed Tronick; Larry J Seidman
Journal:  Schizophr Bull       Date:  2015-04-22       Impact factor: 9.306

4.  Association of Urbanicity With Psychosis in Low- and Middle-Income Countries.

Authors:  Jordan E DeVylder; Ian Kelleher; Monique Lalane; Hans Oh; Bruce G Link; Ai Koyanagi
Journal:  JAMA Psychiatry       Date:  2018-07-01       Impact factor: 21.596

Review 5.  [The significance of stress: its role in the auditory system and the pathogenesis of tinnitus].

Authors:  B Mazurek; T Stöver; H Haupt; B F Klapp; M Adli; J Gross; A J Szczepek
Journal:  HNO       Date:  2010-02       Impact factor: 1.284

6.  Abnormal stress responsivity in a rodent developmental disruption model of schizophrenia.

Authors:  Eric C Zimmerman; Mark Bellaire; Samuel G Ewing; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2013-05-08       Impact factor: 7.853

7.  Childhood trauma and prodromal symptoms among individuals at clinical high risk for psychosis.

Authors:  Judy L Thompson; Meredith Kelly; David Kimhy; Jill M Harkavy-Friedman; Shamir Khan; Julie W Messinger; Scott Schobel; Ray Goetz; Dolores Malaspina; Cheryl Corcoran
Journal:  Schizophr Res       Date:  2009-01-25       Impact factor: 4.939

8.  Female rats are resistant to the long-lasting neurobehavioral changes induced by adolescent stress exposure.

Authors:  Katharina Klinger; Felipe V Gomes; Millie Rincón-Cortés; Anthony A Grace
Journal:  Eur Neuropsychopharmacol       Date:  2019-07-29       Impact factor: 4.600

Review 9.  Attention-deficit/hyperactivity disorder genomics: update for clinicians.

Authors:  Josephine Elia; Jillan Sackett; Terri Turner; Martin Schardt; Shih-Ching Tang; Nicole Kurtz; Maura Dunfey; Nadia A McFarlane; Aita Susi; David Danish; Alice Li; Jenelle Nissley-Tsiopinis; Karin Borgmann-Winter
Journal:  Curr Psychiatry Rep       Date:  2012-10       Impact factor: 5.285

10.  Peripubertal diazepam administration prevents the emergence of dopamine system hyperresponsivity in the MAM developmental disruption model of schizophrenia.

Authors:  Yijuan Du; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2013-04-23       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.